PMID- 38058801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231208
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 13
IP  - 11
DP  - 2023
TI  - Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors 
      vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of 
      advanced hepatocellular carcinoma with portal vein tumor thrombus and 
      arterioportal fistulas.
PG  - 5455-5465
AB  - This study aimed to evaluate the clinical efficacy of hepatic arterial infusion 
      chemotherapy (HAIC) combined with lenvatinib and PD1 inhibitors vs. transarterial 
      chemoembolization (TACE) combined with lenvatinib and PD1 inhibitors in the 
      treatment of unresectable hepatocellular carcinoma (HCC) with portal vein tumor 
      thrombosis (PVTT) and artery-portal shunts (APFs). HCC Patients with PVTT and 
      APFs who received HAIC in combination with PD1 inhibitor or TACE in combination 
      with lenvatinib and PD1 inhibitor from March 2019 to May 2023 in Zhongshan 
      People's Hospital were included. The objective response rate (ORR), disease 
      control rate (DCR), median overall survival (mOS), median progression-free 
      survival (mPFS), median duration of response (mDOR), and adverse events (AEs) 
      were assessed. A total of 95 patients were enrolled in this study, including 34 
      cases in the HAIC+L+P group and 61 cases in the TACE+L+P group. According to the 
      RECIST1.1, the ORR was 52.9% and 27.9%, and the DCR was 100% and 88.5%, 
      respectively (P values =0.03 and < 0.001, respectively). The mOS of HAIC+L+P 
      group and TACE+L+P group were 25.00 and 19.30 months, respectively (P=0.035). The 
      mPFS of the two groups were 21.74 and 8.74 months, respectively (P=0.0066). The 
      mDOR of the two groups was 20.43 and 9.13 months, respectively (P=0.067). 
      Compared with TACE in combination with lenvatinib and PD-1 inhibitors, HAIC 
      (FOLFOX) in combination with lenvatinib and PD-1 inhibitors can improve tumor 
      response and prolong OS, PFS, and DOR in HCC patients with PVTT and APFs.
CI  - AJCR Copyright (c) 2023.
FAU - Lin, Zhipeng
AU  - Lin Z
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
FAU - Chen, Du
AU  - Chen D
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
FAU - Hu, Xiaolong
AU  - Hu X
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
FAU - Huang, Dabei
AU  - Huang D
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
FAU - Chen, Yuan
AU  - Chen Y
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
FAU - Li, Xiaoqun
AU  - Li X
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
FAU - Zou, Xugong
AU  - Zou X
AD  - Department of Interventional Medicine, Zhongshan People's Hospital Zhongshan 
      528400, Guangdong, China.
LA  - eng
PT  - Journal Article
DEP - 20231115
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC10695793
OTO - NOTNLM
OT  - Hepatic arterial infusion chemotherapy
OT  - hepatocellular carcinoma
OT  - immunotherapy
OT  - targeted therapy
OT  - transarterial chemoembolization
COIS- None.
EDAT- 2023/12/07 06:42
MHDA- 2023/12/07 06:43
PMCR- 2023/11/15
CRDT- 2023/12/07 04:11
PHST- 2023/08/23 00:00 [received]
PHST- 2023/10/14 00:00 [accepted]
PHST- 2023/12/07 06:43 [medline]
PHST- 2023/12/07 06:42 [pubmed]
PHST- 2023/12/07 04:11 [entrez]
PHST- 2023/11/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2023 Nov 15;13(11):5455-5465. eCollection 2023.